VIB-UGent Center for Inflammation Research, Zwijnaarde, Ghent 9052, Belgium.
Laboratory for Protein Biochemistry and Biomolecular Engineering, Department of Biochemistry and Microbiology, Ghent University, Ghent 9000, Belgium.
Nat Commun. 2017 Apr 3;8:14937. doi: 10.1038/ncomms14937.
The pro-inflammatory cytokine thymic stromal lymphopoietin (TSLP) is pivotal to the pathophysiology of widespread allergic diseases mediated by type 2 helper T cell (Th2) responses, including asthma and atopic dermatitis. The emergence of human TSLP as a clinical target against asthma calls for maximally harnessing its therapeutic potential via structural and mechanistic considerations. Here we employ an integrative experimental approach focusing on productive and antagonized TSLP complexes and free cytokine. We reveal how cognate receptor TSLPR allosterically activates TSLP to potentiate the recruitment of the shared interleukin 7 receptor α-chain (IL-7Rα) by leveraging the flexibility, conformational heterogeneity and electrostatics of the cytokine. We further show that the monoclonal antibody Tezepelumab partly exploits these principles to neutralize TSLP activity. Finally, we introduce a fusion protein comprising a tandem of the TSLPR and IL-7Rα extracellular domains, which harnesses the mechanistic intricacies of the TSLP-driven receptor complex to manifest high antagonistic potency.
促炎细胞因子胸腺基质淋巴细胞生成素(TSLP)是由 2 型辅助 T 细胞(Th2)反应介导的广泛过敏疾病病理生理学的关键,包括哮喘和特应性皮炎。人类 TSLP 作为治疗哮喘的临床靶点的出现,需要通过结构和机制方面的考虑,最大限度地发挥其治疗潜力。在这里,我们采用了一种综合的实验方法,重点研究了产生活性和拮抗 TSLP 的复合物和游离细胞因子。我们揭示了同源受体 TSLPR 如何通过利用细胞因子的柔韧性、构象异质性和静电作用,变构激活 TSLP,从而增强共享白细胞介素 7 受体 α 链(IL-7Rα)的募集。我们进一步表明,单克隆抗体 Tezepelumab 部分利用了这些原理来中和 TSLP 的活性。最后,我们引入了一种包含 TSLPR 和 IL-7Rα 细胞外结构域串联的融合蛋白,它利用 TSLP 驱动的受体复合物的复杂机制来表现出高拮抗效力。